Literature DB >> 9106695

Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study.

K Lundqvist1, U Broomé.   

Abstract

PURPOSE: A small group of patients with ulcerative colitis (UC) also suffer from primary sclerosing cholangitis (PSC). Genetic and immunologic differences exist between UC patients with and without concomitant PSC. Furthermore, UC patients with PSC are more prone to developing colonic dysplasia/aneuploidy compared with patients with UC only. Because colonic disease activity and treatment with sulfasalazine have been found to be of independent importance for development of colonic carcinoma in UC, this study aims to determine if differences exist concerning colonic disease activity in UC patients with and without PSC.
METHODS: Twenty-nine PSC patients with total colitis were matched to two UC patients with total colitis but without liver disease. Case records and questionnaires were used to gain information on pharmacologic treatment and disease activity.
RESULTS: Observation time was 20 (PSC group) and 23 years (UC only). Number of patients taking prophylactic treatment did not differ between groups. Patients with UC only had received treatment with systemic and local corticosteroids significantly more often than UC patients with PSC (P < 0.05 and P < 0.02). Patients with UC only were hospitalized because of colonic activity significantly more often (P < 0.02). Number of patients undergoing colectomy because of disease activity or number of patients with chronic continuous symptoms did not differ between the two groups.
CONCLUSION: UC in patients with PSC runs a milder course than UC in patients without this complication, although the number of patients taking prophylactic treatment was the same. If lower disease activity reflects differences in pathogenesis of UC in patients with PSC or if it can explain increased risk to develop colonic malignancy in patients with both PSC and UC needs further elucidation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106695     DOI: 10.1007/bf02258391

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  33 in total

Review 1.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Authors:  Peter-Laszlo Lakatos; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

Review 2.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

3.  The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases.

Authors:  G Conway; G Velonias; E Andrews; J J Garber; V Yajnik; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2017-01-20       Impact factor: 8.171

4.  Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Authors:  Kazuhiko Nakamura; Tetsuhide Ito; Kazuhiro Kotoh; Eikichi Ihara; Haruei Ogino; Tsutomu Iwasa; Yoshimasa Tanaka; Yoichiro Iboshi; Ryoichi Takayanagi
Journal:  Clin J Gastroenterol       Date:  2012-01-06

5.  PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  E V Loftus; G C Harewood; C G Loftus; W J Tremaine; W S Harmsen; A R Zinsmeister; D A Jewell; W J Sandborn
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

6.  Colorectal cancer in inflammatory bowel disease.

Authors:  Jonathan Potack; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2008-09-30       Impact factor: 4.519

7.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.

Authors:  Ileana Duca; Patricia Ramírez de la Piscina; Silvia Estrada; Rosario Calderón; Katerina Spicakova; Leire Urtasun; Carlos Marra-López; Salvador Zabaleta; Raquel Bengoa; María Asunción Marcaide; Francisco García-Campos
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 8.  Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis.

Authors:  G V Papatheodoridis; M Hamilton; P K Mistry; B Davidson; K Rolles; A K Burroughs
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

Review 9.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases.

Authors:  T H J Florin; N Pandeya; G L Radford-Smith
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.